Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled Molgramostim in Healthy Adults
NCT02468908Phase 1Completed
- Sponsor
- Savara
- Start
- May 2015
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pulmonary alveolar proteinosis (PAP), bronchiectasis and cystic fibrosis (CF) comparing Molgramostim with Placebo (2 arms). Primary endpoint: Treatment-emergent Adverse Events. Started May 2015; status: completed.
02
Drugs
molgramostim
03
Conditions
pulmonary alveolar proteinosis (PAP)bronchiectasiscystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02468908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02468908.